235 related articles for article (PubMed ID: 28174265)
1. SGK3 sustains ERα signaling and drives acquired aromatase inhibitor resistance through maintaining endoplasmic reticulum homeostasis.
Wang Y; Zhou D; Phung S; Warden C; Rashid R; Chan N; Chen S
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):E1500-E1508. PubMed ID: 28174265
[TBL] [Abstract][Full Text] [Related]
2. Amphiregulin retains ERα expression in acquired aromatase inhibitor resistant breast cancer cells.
Wang Y; Tzeng YT; Chang G; Wang X; Chen S
Endocr Relat Cancer; 2020 Dec; 27(12):671-683. PubMed ID: 33112819
[TBL] [Abstract][Full Text] [Related]
3. Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.
Barone I; Cui Y; Herynk MH; Corona-Rodriguez A; Giordano C; Selever J; Beyer A; Andò S; Fuqua SA
Cancer Res; 2009 Jun; 69(11):4724-32. PubMed ID: 19487288
[TBL] [Abstract][Full Text] [Related]
4. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
[TBL] [Abstract][Full Text] [Related]
5. Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer.
Andruska N; Zheng X; Yang X; Helferich WG; Shapiro DJ
Oncogene; 2015 Jul; 34(29):3760-9. PubMed ID: 25263449
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression.
Andruska ND; Zheng X; Yang X; Mao C; Cherian MM; Mahapatra L; Helferich WG; Shapiro DJ
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4737-42. PubMed ID: 25825714
[TBL] [Abstract][Full Text] [Related]
7. Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy.
Creevey L; Bleach R; Madden SF; Toomey S; Bane FT; Varešlija D; Hill AD; Young LS; McIlroy M
Mol Cancer Ther; 2019 Oct; 18(10):1731-1743. PubMed ID: 31289138
[TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitors and xenograft studies.
Chumsri S; Sabnis GJ; Howes T; Brodie AM
Steroids; 2011 Jul; 76(8):730-5. PubMed ID: 21420993
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
[TBL] [Abstract][Full Text] [Related]
10. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
[TBL] [Abstract][Full Text] [Related]
11. An "omics" approach to determine the mechanisms of acquired aromatase inhibitor resistance.
Chen S
OMICS; 2011 Jun; 15(6):347-52. PubMed ID: 21332390
[TBL] [Abstract][Full Text] [Related]
12. SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells.
Wang Y; Zhou D; Phung S; Masri S; Smith D; Chen S
Mol Endocrinol; 2011 Jan; 25(1):72-82. PubMed ID: 21084382
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
15. ERβ decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway.
Rajapaksa G; Nikolos F; Bado I; Clarke R; Gustafsson JÅ; Thomas C
Oncogene; 2015 Jul; 34(31):4130-41. PubMed ID: 25347741
[TBL] [Abstract][Full Text] [Related]
16. Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.
Chen Z; Wang Y; Warden C; Chen S
J Steroid Biochem Mol Biol; 2015 May; 149():118-27. PubMed ID: 25683269
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
Hirakawa H; Yokoyama Y; Yoshida H; Mizunuma H
J Ovarian Res; 2014 Jan; 7():4. PubMed ID: 24410765
[TBL] [Abstract][Full Text] [Related]
18. The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.
Cairns J; Ingle JN; Kalari KR; Shepherd LE; Kubo M; Goetz MP; Weinshilboum RM; Wang L
Breast Cancer Res; 2019 Apr; 21(1):47. PubMed ID: 30944027
[TBL] [Abstract][Full Text] [Related]
19. IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21.
Lui AJ; Geanes ES; Ogony J; Behbod F; Marquess J; Valdez K; Jewell W; Tawfik O; Lewis-Wambi J
Cancer Lett; 2017 Jul; 399():29-43. PubMed ID: 28411130
[TBL] [Abstract][Full Text] [Related]
20. VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
